Reversible histone glycation is associated with disease-related changes in chromatin architecture

Nat Commun. 2019 Mar 20;10(1):1289. doi: 10.1038/s41467-019-09192-z.

Abstract

Cellular proteins continuously undergo non-enzymatic covalent modifications (NECMs) that accumulate under normal physiological conditions and are stimulated by changes in the cellular microenvironment. Glycation, the hallmark of diabetes, is a prevalent NECM associated with an array of pathologies. Histone proteins are particularly susceptible to NECMs due to their long half-lives and nucleophilic disordered tails that undergo extensive regulatory modifications; however, histone NECMs remain poorly understood. Here we perform a detailed analysis of histone glycation in vitro and in vivo and find it has global ramifications on histone enzymatic PTMs, the assembly and stability of nucleosomes, and chromatin architecture. Importantly, we identify a physiologic regulation mechanism, the enzyme DJ-1, which functions as a potent histone deglycase. Finally, we detect intense histone glycation and DJ-1 overexpression in breast cancer tumors. Collectively, our results suggest an additional mechanism for cellular metabolic damage through epigenetic perturbation, with implications in pathogenesis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylation / drug effects
  • Animals
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Cell Line, Tumor
  • Epigenesis, Genetic*
  • Female
  • Glycation End Products, Advanced / genetics*
  • Glycation End Products, Advanced / metabolism
  • Glycosylation / drug effects
  • Heterografts
  • Histones / genetics
  • Histones / metabolism*
  • Humans
  • Mice
  • Nucleosomes / chemistry*
  • Nucleosomes / metabolism
  • Protein Deglycase DJ-1 / genetics*
  • Protein Deglycase DJ-1 / metabolism
  • Protein Processing, Post-Translational*
  • Pyruvaldehyde / pharmacology
  • Tumor Microenvironment / drug effects

Substances

  • Glycation End Products, Advanced
  • Histones
  • Nucleosomes
  • Pyruvaldehyde
  • PARK7 protein, human
  • Protein Deglycase DJ-1